1 Title: STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in

2 **Refractory Chronic Rhinosinusitis**

- 3 Running title: STAT4 predicts success in CRS surgery
- 4
- 5 Michael R. Abidin M.D.¹, Oral Alpan M.D.² Matthew Plassmeyer PhD², Lina Kozhaya³, Denise
- 6 Loizou RN², Mikail Dogan, M.D³, Zachary Upchurch M.D.¹, Nathan P Manes PhD⁴, Aleksandra
- 7 Nita-Lazar, PhD⁴, Derya Unutmaz, M.D.³, Søren Ulrik Sønder PhD²
- 8
- ⁹ ¹ Metropolitan ENT, 6355 Walker Ln, Alexandria, VA-22310, USA
- ² Amerimmune LLC, 8260 Greensboro Dr VA-22102 McLean, USA
- ³The Jackson Laboratory, Farmington, CT, 06032 USA
- ⁴Functional Cellular Networks Section, Laboratory of Immune System Biology, NIAID, NIH,
- 13 USA
- 14
- 15 ORCID
- 16 Michael R. Abidin M.D.¹ 0000-0001-5679-6667
- 17 Oral Alpan M.D.² 0000-0001-7467-8541
- 18 Matthew Plassmeyer PhD² 0000-0001-8068-2125
- 19 Lina Kozhaya³ 0000-0002-1559-2278
- 20 Denise Loizou RN²
- 21 Zachary Upchurch M.D 0009-0001-1357-5765
- 22 Nathan P Manes PhD⁴ 0000-0001-6701-3314
- 23 Aleksandra Nita-Lazar PhD⁴ 0000-0002-8523-605X

- 24 Mikail Dogan M.D³ 0000-0001-8725-9151
- 25 Derya Unutmaz, M.D.³ 0000-0001-8898-6633
- 26 Søren Ulrik Sønder PhD² 0000-0002-4697-8421
- 27 Corresponding Author: Søren Ulrik Sønder,
- 28 ssonder@amerimmune.com
- 29 571-308-1900
- 30
- 31 Previous publication: This paper is uploaded to Medrxiv
- 32 Keywords: Chronic Refractory Sinusitis, CRS, flow cytometry, T-cells, CD4, STAT4,
- 33 phosphorylation, Cohort study
- 34 **Conflict of interest:** The Author(s) declare(s) that there is no conflict of interest.

35 **Contributions:**

- 36 Michael R. Abidin: Design, Conduct, Analysis
- 37 Oral Alpan: Design, Conduct, Analysis
- 38 Matthew Plassmeyer: Conduct, Analysis
- 39 Lina Kozhaya: Conduct, Analysis
- 40 Denise Loizou: Conduct
- 41 Zachary Upchurch: Conduct
- 42 Nathan P Manes: Conduct, Analysis
- 43 Aleksandra Nita-Lazar: Design
- 44 Mikail Dogan: Conduct, Analysis
- 45 Derya Unutmaz: Design, Analysis

46 Søren Ulrik Sønder: Design, Conduct, Analysis

- 48 Funding source: This study was supported by Amerimmune. This study was supported in part by
- 49 the Intramural Research Program of NIAID, NIH and internal funds to D.U. at Jackson
- 50 Laboratory.

51 Abstract:

52 Objective: Chronic rhinosinusitis (CRS) impacts an estimated 5% to 15% of people worldwide,

53 incurring significant economic healthcare burden. There is a urgent need for the discovery of

54 predictive biomarkers to improve treatment strategies and outcomes for CRS patients.

55 Study design: Cohort study of CRS patients and healthy controls using blood samples.

56 Setting: Out-patient clinics.

57 Methods: Whole blood samples were collected for flow cytometric analysis. Mechanistic studies58 involved the transfection of human primary T cells and Jurkat cells.

59 Results: Our analysis began with a 63-69 year-old female patient diagnosed with refractory

60 CRS,. Despite undergoing multiple surgeries, she continually faced sinus infections. Whole

61 exome sequencing pinpointed a heterozygous IL-12Rb1 mutation situated in the linker region

62 adjacent to the cytokine binding domain. When subjected to IL-12 stimulation, the patient's CD4

63 T-cells exhibited diminished STAT4 phosphorylation. However, computer modeling or T-cell

64 lines harboring the same IL-12 receptor mutation did not corroborate the hypothesis that IL-

65 12Rb could be responsible for the reduced phosphorylation of STAT4 by IL-12 stimulation.

66 Upon expanding our investigation to a broader CRS patient group using the pSTAT4 assay, we

67 discerned a subset of refractory CRS patients with abnormally low STAT4 phosphorylation.

68 The deficiency showed improvement both in-vitro and in-vivo after exposure to *Latilactobacillus*

69 *sakei* (aka *Lactobacillus sakei*), an effect at least partially dependent on IL-12.

70 Conclusion: In refractory CRS patients, an identified STAT4 defect correlates with poor clinical

71 outcomes after sinus surgery, which can be therapeutically targeted by *Latilactobacillus sakei*

72 treatment. Prospective double-blind placebo-controlled trials are needed to validate our findings.

74

75 Introduction

76	The intricate web of cellular interactions and cytokine signaling pathways plays a pivotal role in
77	orchestrating the immune response to pathogens. Central to this network is the IL-12/IFN- γ axis,
78	a well-recognized T-helper 1 (Th1) pathway in mediating protective immunity against
79	intracellular pathogens [1]. Interleukin-12 (IL-12), produced predominantly by antigen-
80	presenting cells like dendritic cells and macrophages [2], induces the production of interferon-
81	gamma (IFN- γ) from natural killer cells and T lymphocytes [3,4]. IFN- γ , in turn, acts to
82	stimulate the innate and adaptive arms of the immune system, promoting cellular immunity and
83	controlling pathogen proliferation. IL12R β 1 is a subunit of both the IL-12 and IL-23 receptor
84	complex and binds to the p40 subunit of IL-12 and IL-23. Upon infection with intracellular
85	bacteria, phagocytes are activated and secrete cytokines including IL-12, a signature cytokine for
86	Th1 responses. Following binding of IL-12 to its receptor, STAT4 is phosphorylated which is
87	essential for IFNγ production[1,5,6].

88

89 Disruption of this axis could compromise the ability of the immune system to handle microbial 90 challenges, leading to persistent infections and prolonged inflammation. Indeed, a balanced IL-91 12/IFN-γ response is essential to clear pathogens, maintain mucosal homeostasis, and prevent tissue damage in the sinuses[1]. Furthermore, recurrent infections, which denote a failure of the 92 93 immune system to provide lasting protection after initial exposure to a pathogen, may also be linked to perturbations in the IL-12/IFN- γ pathway. An impaired or inadequate IL-12-driven 94 95 IFN-y response may not only decrease resistance to primary infections but might also reduce 96 immune memory, rendering individuals more susceptible to recurrent bouts of infections despite

97 adequate surgical intervention [1,7–13]. Although T-cell defects are the most common immune 98 disorder in chronic rhinosinusitis (CRS), clinical workup towards its identification is rarely 99 performed. 100 101 Various dietary supplements have been demonstrated to enhance Th1 responses. Among them included are various lactobacillus probiotic supplements. Although the role of lactobacillus 102 103 containing supplements, taken orally or topically, is unproven in patients with CRS, small sized 104 studies and anecdotal reports did find correlations with clinical outcomes in the surgical healing process [14–20]. Data from preliminary studies have shown mixed results in patients receiving 105 probiotics containing lactobacilli species. Lactobacilli have the potential of inducing IL-12 from 106 macrophages [21–23].

108

107

109 Our investigation began with a case of refractory chronic rhinosinusitis (RCRS) associated with a heterozygous IL-12 receptor mutation. Despite observing decreased STAT4 phosphorylation in 110 111 response to IL-12 stimulation in both the patient and her children, the mutation itself was not proven to be the cause. Further research revealed this decreased phosphorylation to be a common 112 characteristic in a broader RCRS patient cohort. Insights into the IL-12/IFN-y signaling 113 114 pathway's role in CRS may unveil new therapeutic targets to enhance immunity, alleviate chronic inflammation, and decrease recurrent infections. 115 116

Materials and Methods: 117

118 Patients and ethical statement.

119	The studies involving human participants were reviewed and approved by Western Institutional
120	Review Board (WIRB) Protocol #1285028. Written, informed consent was obtained from the
121	individuals for the publication of any potentially identifiable images or data included in this
122	article. Individuals undergoing steroid or MoAB treatments targeting the IL-12 pathway were
123	excluded from the study. The grouping of CRS and RCRS patient was done according to
124	published guidelines[24,25].
125	Lactobacilli supplements and administration: Lactobasillus sakei proBio65 as a nasal rinse 1/4 th
126	teaspoon of Lanto Health powder (240 mg) in 2 tablespoons of normal saline nasal rinses once a
127	day and 240 mg twice a day in food.
128	Genetics: Whole Exome Sequencing was carried out by GeneDX (Gaithersburg, MD).
129	Subsequently Sanger sequencing was carried out by Macrogen (Rockville, MD).
120	
130	
130	Flow cytometry and cell culture.
130 131 132	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4,
130 131 132 133	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4, CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The
130 131 132 133 134	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4, CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The percentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) were
130 131 132 133 134 135	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4, CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The percentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) were measured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1µg/ml) in the
130 131 132 133 134 135 136	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4, CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The percentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) were measured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1µg/ml) in the presence of brefeldin A for 4 hours. The cells were then permeabilized and stained with
130 131 132 133 134 135 136 137	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4, CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The percentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) were measured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1µg/ml) in the presence of brefeldin A for 4 hours. The cells were then permeabilized and stained with antibodies against CD3, CD4, CD8, CD45RA, CCR6, IFNγ-APC and IL17-PE (BD Bioscience,
130 131 132 133 134 135 136 137 138	Flow cytometry and cell culture.Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4,CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. Thepercentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) weremeasured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1µg/ml) in thepresence of brefeldin A for 4 hours. The cells were then permeabilized and stained withantibodies against CD3, CD4, CD8, CD45RA, CCR6, IFNγ-APC and IL17-PE (BD Bioscience,San Jose, CA). Acquisition was set to 30000 CD3 ⁺ events. The Th1 mediated IFNγ response was
130 131 132 133 134 135 136 137 138 139	Flow cytometry and cell culture.Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4,CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. Thepercentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) weremeasured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1µg/ml) in thepresence of brefeldin A for 4 hours. The cells were then permeabilized and stained withantibodies against CD3, CD4, CD8, CD45RA, CCR6, IFNγ-APC and IL17-PE (BD Bioscience,San Jose, CA). Acquisition was set to 30000 CD3 ⁺ events. The Th1 mediated IFNγ response wasstudied by incubating the PBMC for 72 hours in the presents of IL-2 (100 U/ml), IL-12 (100
130 131 132 133 134 135 136 137 138 139 140	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4, CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The percentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) were measured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1µg/ml) in the presence of brefeldin A for 4 hours. The cells were then permeabilized and stained with antibodies against CD3, CD4, CD8, CD45RA, CCR6, IFNγ-APC and IL17-PE (BD Bioscience, San Jose, CA). Acquisition was set to 30000 CD3 ⁺ events. The Th1 mediated IFNγ response was studied by incubating the PBMC for 72 hours in the presents of IL-2 (100 U/ml), IL-12 (100
130 131 132 133 134 135 136 137 138 139 140 141	Flow cytometry and cell culture. Staining for IL-12Rβ1 expression was performed using antibodies against IL-12Rβ1, CD4, CD20 and CD3. For the Th1 & Th17 assay PBMC were isolated by gradient centrifugation. The percentages of CD4 T-cells capable of producing IFNγ (Th1 cells) and IL-17 (Th17 cells) were measured by stimulating the PBMC with PMA (50ng/ml) and ionomycin (1µg/ml) in the presence of brefeldin A for 4 hours. The cells were then permeabilized and stained with antibodies against CD3, CD4, CD8, CD45RA, CCR6, IFNγ-APC and IL17-PE (BD Bioscience, San Jose, CA). Acquisition was set to 30000 CD3 ⁺ events. The Th1 mediated IFNγ response was studied by incubating the PBMC for 72 hours in the presents of IL-2 (100 U/ml), IL-12 (100 ng/ml), IL-18 (50 ng/ml), and Dynabeads Human T-Activator CD3/CD28 (10µl/ml). The cells were then fixed, permeabilized and stained with antibodies against CD3, CD4, IFNγ

142	and fixable viability dye 780. Acquisition was set to 20000 $CD4^+$ events. The CAP and CLIA
143	validated pSTAT4 stimulation assays were carried out using whole blood stimulated with IL-12
144	(100ng/ml) for various timepoints, followed by staining with antibodies against CD3, CD4,
145	CD45RO, and pSTAT4(pY693) (BD Bioscience, San Jose, CA). Acquisition was set to 20000
146	CD4 ⁺ events with a LLOQ of 2500[26]. All samples were acquired on a 3 laser/10 color BD
147	FACSCanto. The instrument has been CAP (College of American Pathologists) and CLIA
148	validated for clinical diagnostic studies. The individual antibody concentrations were optimized
149	for maximum separation of the populations[27].
150	
151	One capsule of Super 8 HI-Potency Probiotic from Flora containing L. acidophilus, L.
152	rhamnosus, L. salivarius, L. plantarum, L. casei, B. bifidum and B. longum was resuspended in
153	PBS and a total of 10^6 cells were added to 10^6 PBMC in the presence or absence of IL-12
154	neutralizing antibodies (BioRad) and incubated for 18 hours at 37°C. Control samples were
155	stimulated with IL-12 for 2 hours. The experiment was done six times and representative plots
156	are shown. The percentage reduction in pSTAT4 phosphorylation was calculated using the
157	CD45RO ⁺ /pSTAT4 ⁺ value as ((IL12AB+lactobacilli)-(unstimulated))*100/((lactobacilli)-
158	(unstimulated))
159	

160 Data analysis and modelling.

161 Data analysis of flow cytometry data was performed using FCS Express software (De Novo

software, Glendale, CA). All data comparisons were analyzed as paired, two tailed, two-sample

unequal variance using Student's t-test to determine significance. A p-value less than 0.05 was

164 considered significant, p < 0.05, p < 0.01.

1	6	5
-	v	-

- 166 Protein structure modeling was performed using AlphaFold [28]. The resulting models were
- aligned and visualized using Chimera[29].
- 168

169 Plasmid constructs

- 170 Human codon-optimized wild-type IL-12Rb1 and IL-12Rb2 protein sequences were synthesized
- by MolecularCloud (HG11674-UT and HG10145-UT, respectively) and then cloned into
- 172 lentiviral plasmid constructs with RFP and GFP reporters, respectively. The overlap extension
- 173 PCR method was used to generate the mutant IL12Rb1 Q238E protein sequence and clone it into
- the lentivector. IL-12Rb1 Q238E sequence was then confirmed using sequencing by Eton Bio.
- 175 Primer sequences are available upon request.
- 176

177 Lentivirus production

- 178 The lentiviruses pseudotyped with vesicular stomatitis virus G protein envelope were generated
- 179 with HEK293T cells using Lipofectamine 3000 (Invitrogen) according to the manufacturer's
- 180 protocol as previously described [30].

181

182 Engineering primary human T cells and Jurkat cells

- 183 Healthy adult blood was obtained from AllCells. Primary CD4 T cells were isolated, activated,
- transduced to overexpress IL12Rb1 wild-type or mutant, and proliferated as previously described
- 185 [31]. Total PBMC were activated with antiCD3/anti-CD28 dynabeads (Invitrogen) and expanded
- in IL-2 (10ng/ml) containing media. To generate IL12Rb1 wild-type or mutant and IL12Rb2
- 187 overexpressing Jurkat cells, wild-type Jurkats were transduced with the IL-12Rb2 lentiviruses,

188	co-expressing GFP marker, and superinfected with IL-12Rb1 wild-type or IL-12Rb1 Q238E
189	lentiviruses, co-expressing RFP marker, at MOI=3. The infection levels were determined by GFP
190	or RFP expression using flow cytometry analysis. Engineered Jurkat cells were later single-cell
191	cloned with FACSAria Fusion (BD Biosciences). To further confirm IL-12 receptors
192	overexpression, transduced cells were stained with IL-12Rb1 (R&D) and IL-12Rb2 (Biolegend)
193	antibodies. For phospho-Stat4 staining, total resting or activated PBMCs, engineered primary
194	CD4 T or Jurkat cells were stimulated with different concentrations of IL-12 (R&D) for 90
195	minutes. Cells were collected, stained with fixable viability dye (eBiosciences) and surface
196	markers including IL-12Rb1 (R&D biosystems), CD3, CD4 and CD8 (Biolegend) to identify
197	PBMC populations, washed then fixed with Cytofix buffer (BD) prewarmed to 37°C for 10 min.
198	After spinning down, the cells were permeabilized with ice-cold Phosflow Perm buffer III (BD)
199	on ice for 30 min and were stained with phospho-Stat4 (pY693) antibody (BD) or total Stat4
200	primary antibody followed by anti-rabbit secondary antibody (both from Invitrogen). Stained
201	cells were analyzed on BD Symphony A5 flow cytometer (BD Biosciences). Flow cytometry
202	data was analyzed using FlowJo software.
203	
204	
205	Statistical Analyses and Reproducibility

All statistical analyses were performed, and graphs were prepared using GraphPad Prism V9 software. Each experiment was performed at least three times and non-parametric t-tests were used for statistical significance analyses.

209

210 **Results**

211 Identification of a Th1 defect in a family of patients with RCRS.

212 The patient is a 63-69 year-old Caucasian female with a long-standing history of chronic 213 pansinusitis without polyps, and osteomyelitis of the right maxillary sinus wall. Sinus cultures 214 grew methicillin resistant S. aureus and Klebsiella species on multiple occasions. Patients 215 underwent multiple sinus surgeries and procedures involving ethmoid, maxillary and frontal sinuses. Sinus surgical pathology results show predominantly neutrophilic infiltrates (Figure 1A). 216 217 The patient's immune evaluation showed slight hypogammaglobulinemia (400-500 mg/dL 218 range) on multiple occasions along with poor responses to S. pneumoniae serotypes (3/14 of the)219 serotypes with protective levels above 1.3 mcg/ml despite multiple boosters with Pneumovax23). 220 Serum IgM, IgA and IgE levels were within normal limits. The patient's B cells expressed normal CD27, IgG, IgA, IgM and IgD, arguing against a primary antibody deficiency disorder. 221 222 T-cells, including T-cell subsets and NK cells were normal for absolute numbers and 223 percentages. Given the poor response to antibiotic therapies, and persistently borderline low IgG, 224 the patient was started on IgG replacement therapy which resulted in partial clinical 225 improvement of the sinus disease. 226 227 Since the patient's clinical presentation was not fully explained by the low serum IgG and only a

partial clinical response to the IgG replacement therapy, whole exome sequencing was
performed, which revealed a heterozygous mutation in the *IL12RB1* gene, 712 C>G resulting in
the p.Gln238Glu variant. The variance was confirmed by Sanger sequencing in the patient as
well as in four of her five children (Figure 1B+1C). The p.Gln238Glu variant is classified as a
variant of uncertain significance (VUS) in ClinVar[32]. The structure modeling of the molecular
defect maps it to the linker region to the cytokine binding domain (Supplemental figure 1). The

234	mutation did not affect the expression level of IL12Rb1 receptor on the cell surface or the ability
235	of CD4 cells to produce IL-17 or IFN γ in response to general activation by PMA plus ionomycin
236	(Figure 1D and Figure 2). We then hypothesized that it could be possible for the mutated
237	receptor to still form complexes with the IL23R or IL-12R β 2 but not bind IL-12 or IL-23 in a
238	conformation that activates downstream signaling. The patient's RCRS history led us to focus on
239	IL-12/Th1 rather than IL-23/Th17 defects. To assess the potential role of the $IL12R\beta1$ mutation
240	on IL-12 signaling, we measured IFN γ production by stimulating PBMC from the patient and
241	healthy age matched controls after IL12R β 1 specific stimulation. The expected result for a
242	heterozygous patient would be a reduction rather than abolishing IL-12 signaling. The results
243	show that the percentages of the CD4 ⁺ T cells that are IFN γ^+ after stimulation are 4.6% for the
244	healthy control versus 5.2% for the patient. However, only 0.5% of the patient's $CD4^+$ T-cells
245	are IFN γ^{high} compared to 2.8% in the healthy control (Figure 3).

246

247 To identify the Th1 defect, we measured the phosphorylation of STAT4 in response to IL-12 stimulation in CD3⁺/CD4⁺/CD45RO⁺ cells at various time points between 0 and 5 hours. The 248 result for the patient is an average of three samples each collected a month apart. They were 249 250 compared to a group of age matched healthy controls (n=5) and patients with various well 251 defined immune deficiencies requiring antibody replacement therapy (n=5). Healthy controls 252 showed an increase in percentage of p-STAT4 positive T-helper memory cells after 30 minutes 253 of stimulation with IL-12 which peaked after 60-120 minutes followed by a slow decrease after 254 180 minutes. The patient's p-STAT4 response was significantly blunted at all time points. 255 (Figure 4A and 4B).

We subsequently tested four of the patient's adult children. The IL-12 induced STAT4
phosphorylation showed that the three siblings with the mutation showed a lower peak in STAT4
phosphorylation after 60 minutes compared to the sibling without the mutation (Figure 4C). One
of the three siblings with the mutation had a history of recurrent sinusitis and pneumonia.
Transfection Experiments to show the impact of Q2883 mutation on primary T cells.
The modeling of the IL12 receptor did not show any difference in the folding of the receptor

between the wild type and the p.Gln238Glu variant (Supplemental Figure 1). To determine

whether the mutated IL12 receptor is the cause of the defective STAT4 phosphorylation, we first

engineered primary CD4⁺ T cells to overexpress the WT or the mutated IL-12Rb1 (Supplemental

Figure 2). We saw no difference in the phosphorylation of STAT4 on IL12 stimulation in these

primary CD4⁺ T cells when compared those engineered to express wild-type or mutant IL12Rb1.

269 (Supplemental Figure 3). A significant challenge posed by this system is the mosaicism of the

cells harboring the mutant receptors, as they also express normal IL12b1 receptors constitutively.

271 Consequently, IL12 may exhibit a preferential activation of the normal receptor, complicating

the functional analysis of the mutant variant. To address this issue, we utilized Jurkat cells,

which are deficient in IL12b1. Jurkat cells also express high levels of STAT4 constitutively

274 (Figure 5). Thus, we genetically expressed either the wild-type (WT) or the mutant variant of

this receptor in Jurkat cells along with the IL-12Rb2, which is required to form heterodimer with

276 IL-12Rb1 for the signaling via IL-12 (Supplemental Figure 4). In these genetically engineered

277 Jurkat cells, upon stimulation with IL-12 we could detect phosphorylation of STAT4, but not

wild type Jurkat line, suggesting efficient reconstitution of the receptor complex for this

signaling pathway. Overexpression of IL12Rb1 and IL12Rb2 genes also led to high level

280	expression of these receptors on cell surface of the Jurkat cells and was comparable between the
281	mutant and the WT IL-12Rb1 expressing cells (Figure 6A). Upon stimulation of with IL-12,
282	there was no difference for STAT4 phosphorylation between the Jurkat cells expressing WT or
283	the mutant IL12Rb1 (Figure 6B). As we couldn't establish a conclusive link between the
284	patient's mutation and the signaling defect, we opted to examine a larger number of individual
285	clones.
286	
287	We therefore asked if there factors other than IL-12R and STAT4 expression could potentially
288	affect the IL-12 signaling. We reasoned such differences could only be detected at single cell
289	clone levels. Accordingly, Jurkat cells engineered to overexpress WT IL-12Rb2 and WT IL-
290	12Rb1 were single cell sorted based on GFP and RFP expression, single cell clones were
291	expanded for 3-4 weeks and pStat4 levels in different clones were measured after IL-12
292	stimulation. Remarkably, while the IL-12 receptor levels were high and comparable among all
293	clones (over 40 clones were analyzed), pSTAT4 levels were widely different between clones
294	stimulated with IL-12 (Figure 7A). These results suggest that yet to be determined intermediary
295	factors between the receptor and STAT phosphorylation, for example kinases such as Tyk2 or
296	Jak2, may influence the efficiency, which could explain the results observed in the family
297	reported in this article (Figure 7B).
298	

299

300 Validation of the pSTAT4 assay

In the context of CRS, dysbiosis in the upper airway microbiome can influence IL12 signaling.
 For example, mucin-fermenting bacteria in CRS may degrade and ferment mucins, altering the

airway environment and promoting inflammation that could disrupt IL12 signaling [33].

- 304 Additionally, elevated short chain fatty acid levels in CRS mucus may also impact this pathway
- 305 [34]. This suggests that apart from genetic factors, extrinsic factors, such as microbial
- imbalances could contribute to IL12 signaling defects in CRS.

307 To test this hypothesis, we next sought to test a larger cohort of patients with RCRS, to see if the

308 variability we see in the pSTAT4 levels in the clones is reflected between patients. The

309 phosphorylation of STAT4 after IL-12 stimulation allows for a functional readout of the

signaling regardless of the location of the genetic variations in the IL-12/IFNγ axis or molecules

that influence it, which can vary between patients. To do this, we first validated the assay so that

the results are consistent and that it can be included in the clinical workup of patients with CRS.

The previously published pSTAT4 assay, used to study IL-12 receptor mutations, relied on the

314 hypothetical approach of maximizing IL-12 receptor expression by inducing blastogenesis using

315 PHA, a process that typically takes 5-7 days. The blasts are then subsequently stimulated with

316 IL-12 [35–37]. This approach can be employed in a research setting to demonstrate that IL-12

receptor mutations can disrupt IL-12 signaling. However, it is not well-suited for routine clinical

testing due to the challenges associated with validating a multistep process that involves

319 numerous variables in blastogenesis. Additionally, blasts may not accurately reflect a

320 physiological response in vivo, as the majority of circulating cells are not in a continuous

activated state. Furthermore, our findings indicate that the expression of T cell surface IL-12

receptors remains unchanged between resting T cells and blasts. (Supplemental Figure 5). The

323 pSTAT4 assay performed on resting primary T cells and validated under CAP/CLIA utilizes

whole blood within 24 hours [26]. The assay measures STAT4 phosphorylation at multiple time

points, extending up to 2 hours, and can be finalized within 5 hours. It exhibits high

- reproducibility and is accompanied by reference ranges, enabling us to assess a patient's
- 327 condition without the need to include a group of healthy controls.
- 328

329 pSTAT4 to screen CRS for prolonged surgical recovery.

In addition to the results from our Jurkat clones showing variability in STAT4 phosphorylation, 330 the published reports on T cell defects in up to 56% of RCRS patients supported our approach to 331 332 screen a larger cohort of RCRS patients [38]. To assess the clinical relevance of our finding in 333 the larger RCRS population, we used the IL-12 induced pSTAT4 as a screening assay in 147 334 RCRS patients requiring surgery (Figure 8 and Supplemental Figure 6). These RCRS patients 335 presented with infections of Klebsiella, Staphylococcus, Serratia and Burkholderia species isolated from sinus cultures, and had history of multiple sinus procedures, no polyps. These 336 337 patient's nasal mucosa showed areas of inflammation, often with one side or another showing much worse disease, rather than widespread inflammation. Chronic inflammatory infiltrates were 338 339 common to all RCRS patients' tissue specimens, performed as a part of their post-surgical 340 specimen processing. Bad surgical outcome was defined as requiring more than two courses of antibiotic therapy within the first 6 months after surgery. Low STAT4 phosphorylation 341 342 correlated with prolonged surgical recovery of lengthy healing process as well as persistence of 343 the sinus infections. None of the individuals in the control group or the patients with a good surgical outcome had a pSTAT4 value below 5% whereas most of the patients with poor surgical 344 345 outcome had a value below 5%. To test if a soluble factor (i.e. anti-cytokine antibody) was responsible for low STAT4 phosphorylation, we performed the experiments on health subjects 346 347 CD4 T cells using RCRS patient serum. Serum of RCRS patients with low pSTAT4 did not

result in healthy patients' cells down-regulating STAT4 phosphorylation in response to IL-12
stimulation (Supplemental figure 7).

350

351 Effect of Lactobacilli on STAT4 phosphorylation in-vitro and in vivo

In our follow-up experiments, we explored the potential impact of lactobacilli on pSTAT4 352 353 phosphorylation. This investigation was prompted by data suggesting that specific lactobacilli 354 strains can trigger IL-12 production in macrophages and by anecdotal observations within our 355 group regarding the potential clinical advantages of probiotics in chronic sinus disease. Our 356 results demonstrated that when PBMCs were exposed to a lactobacilli solution containing L. 357 acidophilus for 18 hours, STAT4 phosphorylation was induced, even in the absence of exogenous IL-12 supplementation. Intriguingly, when the lactobacilli solution was introduced to 358 359 PBMCs of patients exhibiting low STAT4 phosphorylation in their CD4 T-cells, there was a 360 notable enhancement in STAT4 phosphorylation. This effect was partially inhibited by 361 neutralizing anti-IL12 antibodies (Figure 9). This suggests that the probiotic's effect can be 362 attributed to IL12 production but contributions from an IL-12 independent pathway could not be ruled out. The phosphorylation of STAT4 by lactobacilli, as well as its inhibition of IL-12, 363 exhibits specificity to both the bacterial strain and the host (Supplemental Figure 8). 364 365

In light of these findings, we conducted a retrospective review of medical records for 25 CRS patients who were administered *Latilactobacillus sakei*, a strain reported for its ability to induce exceptionally high IL-12 levels [39]. We gauged the patients' response to the probiotic by correlating the number of postoperative office visits and change in pSTAT4 levels pre-and postprobiotic use in a 1-year period. The results present pSTAT4 levels as a percentage change, and

the outpatient data reflect the difference in visit frequency. Our analysis underscored a positive

372 correlation between the frequency of patients' post-surgical visits and the pSTAT4

phosphorylation in their CD4 T cells (Figure 10).

374

375 **Discussion**

376 CRS remains a nuanced pathology, both in its presentation and underlying etiologies. In this

study, we started out with exploring a VUS in the IL-12 receptor beta 1 of an RCRS patient.

378 Despite the patient's receptor expressing normally on peripheral blood T-helper cells, our

discoveries highlighted a compromised IL-12 signaling. Even though there is a correlation in the

patient's family between individuals with the mutation and low pSTAT4 response we were

unable to show an effect of the mutation in computational structural simulation models or by *in*

vitro transfection experiments.

383

384 Broadening our scope, we undertook a validated pSTAT4 assay across an expansive cohort of RCRS patients. The outcome was illuminating; diminished STAT4 phosphorylation in CD4 T-385 386 cells heralded poor post-surgical recoveries. While this finding seemed to be a validation of prior 387 research emphasizing T-cells' pivotal roles in RCRS, it also accentuated a conspicuous gap in clinical practice: the lack of routine cellular immunity assessments of these patients, despite their 388 389 potential diagnostic importance. The common practice of immune evaluation of CRS involves 390 measuring serum quantitative antibody levels, which, more often than not, provide inconclusive results [25,40,41]. As this research underscores specific defects in T cell function and offers a 391 392 clinically validated diagnostic tool, we anticipate a paradigm shift towards more tailored 393 therapeutic approaches for RCRS. However, unveiling the exact mechanics behind impaired IL-

12-mediated STAT4 phosphorylation remains to be determined, the deciphering of which couldusher in therapeutic breakthroughs.

396

397 Another riveting aspect of our study revolves around the interplay between Lactobacillus species and the immune system. With their presence predominantly in the human gut, Lactobacillus 398 species' interactions with macrophages can influence cytokine profiles, including IL-12 [42]. We 399 400 confirmed this in our *in vitro* analysis using neutralizing IL-12 antibodies which reduced the 401 effect of L. acidophilus. Furthermore, the L. acidophilus was able to induce STAT4 402 phosphorylation in the absence of any exogenous IL-12. But not all Lactobacilli are created equal. Potentially, strain-specific variability can exist in their potency to modulate IL-12, 403 potentially attributed to differences in their cell walls [43]. This study further delves into this 404 variability, reinforcing the importance of strategic Lactobacillus selection in potential therapeutic 405 406 endeavors. The precise mechanism of Lactobacillus stimulation of T cells is not entirely known 407 and our data shows both IL-12 independent as well as dependent phosphorylation of STAT4. 408 The STAT4 phosphorylation we observe in Figure 9A is lower than what we see when saturating the blood sample with IL-12, but it is likely to be adequate, in vivo, to activate and poise the Th-1 409 cells in patients with low pSTAT4 response and lead to improved clinical outcomes in 410 411 postsurgical RCRS patients.

412

Our Lactobacillus data provide important insights into the inconsistent findings in the literature
concerning the clinical effects of Lactobacillus on Chronic Rhinosinusitis (CRS) outcomes. The
data highlight two key factors: Firstly, the specific strains of probiotics and individual host
characteristics significantly influence STAT4 phosphorylation. This effect's strength and its IL-

417 12 dependence vary, as evidenced by the inhibition assays presented in Figure 5 and 418 Supplementary Figure 8. Future research should identify the probiotic structural components 419 responsible for these effects. Secondly, the choice of clinical endpoints is crucial. Given that 420 STAT4 phosphorylation is pivotal in regulating Th1 cell responses, our research prioritized post-421 surgical wound healing rather than improvements in clinical symptoms or reductions in sinus 422 infection rates. [44–46]. The process of wound healing begins with an immediate inflammatory 423 response, seeing an influx of various cellular actors. Th1 cells, through their influence on 424 macrophages and fibroblasts and their production of IFN- γ , impact collagen synthesis, the 425 bedrock of tissue repair [47]. However, maintaining a balance in Th1 activity is paramount. An 426 overwhelming or inadequate Th1 response can either prolong inflammation or inadequately support the initial healing phases, respectively. As such, understanding Th1 activity, primarily 427 428 via STAT4 phosphorylation, provides invaluable insights into predicting and optimizing surgical 429 outcomes. Furthermore, the microbiota can induce an adaptive immune response that can couple 430 antimicrobial function with tissue repair and wound healing [48]. It has been shown that non-431 classical MHC class I molecules, an evolutionarily ancient arm of the immune system, can 432 promote immunity to the microbiota, such as Lactobacillus, and subsequently affect cytokine signaling, including IL-12 [49]. To enhance our understanding of Recurrent Chronic 433 434 Rhinosinusitis (RCRS), it is crucial to conduct prospective studies focusing on the IL-12 pathway. Investigating its specific functions could provide insights into its dual role in infection 435 436 control and inflammation regulation.

438	A limitation of our study is that it was not designed prospectively, and it depended on the
439	analysis of retrospective review of patient charts. To further corroborate our clinical findings,
440	future studies should be prospective, randomized, and placebo controlled.
441	
442	Finally, our research underscores the critical role of Laboratory Developed Tests (LDTs) in
443	enhancing clinical diagnostics and patient care, with a special focus on the pSTAT4 assay as an
444	example. Unlike test kits cleared by the Food and Drug Administration (FDA), LDTs bridge the
445	gap in diagnosing complex or rare conditions. Their ability to rapidly integrate cutting-edge
446	diagnostic methods makes them an essential tool in the dynamic healthcare environment,
447	especially when leveraged by skilled clinicians. The pSTAT4 test, in particular, has shown
448	promise as a predictor of outcomes following sinus surgeries, potentially revolutionizing the
449	management strategies for RCRS. Given these findings, there is a compelling case for the
450	broader adoption of LDTs like pSTAT4 in clinical settings and a call for more research to further
451	establish their utility and impact on patient care trajectories.
452	
453	Conclusion

454 As our grasp of RCRS and its complex underlying mechanisms grows, evaluating T-cell defects

using the STAT4 phosphorylation assay described in this study emerges as a particularly

456 promising avenue. These innovative diagnostic and therapeutic strategies that evolve from them,

457 have the potential to transform our management of CRS. When utilized with precision, they offer

458 a path toward alleviating the substantial strain that CRS places on healthcare systems.

459

460 **References**

- 461 [1] Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways.
 462 Immunol Rev 2005;203:38–47. https://doi.org/10.1111/j.0105-2896.2005.00227.x.
- Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification
 of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human
 lymphocytes. J Exp Med 1989;170:827–45. https://doi.org/10.1084/jem.170.3.827.
- 466 [3] Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection,
 467 inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009;8:40–52.
 468 https://doi.org/10.2174/187152809787582507.
- 469 [4] Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res
 470 2004;24:439–54. https://doi.org/10.1089/1079990041689665.
- 471 [5] Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, et al. STAT4 serine
 472 phosphorylation is critical for IL-12-induced IFN-γ production but not for cell proliferation. Proc
 473 Natl Acad Sci USA 2002;99:12281–6. https://doi.org/10.1073/pnas.182618999.
- Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu C-Y, et al. A functional interleukin 12
 receptor complex is composed of two β-type cytokine receptor subunits. Proc Natl Acad Sci USA
 1996;93:14002–7. https://doi.org/10.1073/pnas.93.24.14002.
- 477 [7] De Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al.
 478 Revisiting Human IL-12Rβ1 Deficiency: A Survey of 141 Patients From 30 Countries. Medicine
 479 2010:89:381–402. https://doi.org/10.1097/MD.0b013e3181fdd832.
- 480 [8] Van De Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, Metin
 481 A, et al. IL-12Rβ1 Deficiency: Mutation Update and Description of the *IL12RB1* Variation
 482 Database. Human Mutation 2013;34:1329–39. https://doi.org/10.1002/humu.22380.
- Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, et al. Low Penetrance,
 Broad Resistance, and Favorable Outcome of Interleukin 12 Receptor β1 Deficiency. The Journal of
 Experimental Medicine 2003;197:527–35. https://doi.org/10.1084/jem.20021769.
- [10] Rosain J, Oleaga-Quintas C, Deswarte C, Verdin H, Marot S, Syridou G, et al. A Variety of Alu Mediated Copy Number Variations Can Underlie IL-12Rβ1 Deficiency. J Clin Immunol
 2018;38:617–27. https://doi.org/10.1007/s10875-018-0527-6.
- [11] Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L. Mendelian susceptibility to mycobacterial
 disease: Genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Seminars
 in Immunology 2014;26:454–70. https://doi.org/10.1016/j.smim.2014.09.008.
- [12] Cleary AM, Tu W, Enright A, Giffon T, Dewaal-Malefyt R, Gutierrez K, et al. Impaired
 Accumulation and Function of Memory CD4 T Cells in Human IL-12 Receptor β1 Deficiency. The
 Journal of Immunology 2003;170:597–603. https://doi.org/10.4049/jimmunol.170.1.597.
- [13] Jacobson NG, Szabo SJ, Güler ML, Gorham JD, Murphy KM. Regulation of interleukin-12
 signalling during T helper phenotype development. Adv Exp Med Biol 1996;409:61–73.
 https://doi.org/10.1007/978-1-4615-5855-2_9.
- 498 [14] Smith A, Buchinsky FJ, Post JC. Eradicating chronic ear, nose, and throat infections: a
 499 systematically conducted literature review of advances in biofilm treatment. Otolaryngol Head Neck
 500 Surg 2011;144:338–47. https://doi.org/10.1177/0194599810391620.
- [15] Lee VS. Topical Irrigations for Chronic Rhinosinusitis. Immunol Allergy Clin North Am
 2020;40:317–28. https://doi.org/10.1016/j.iac.2019.12.014.
- [16] Czibulka A. Probiotics for Otolaryngologic Disorders. Otolaryngol Clin North Am 2022;55:939–46.
 https://doi.org/10.1016/j.otc.2022.06.003.
- [17] Psaltis AJ, Mackenzie BW, Cope EK, Ramakrishnan VR. Unraveling the role of the microbiome in chronic rhinosinusitis. J Allergy Clin Immunol 2022;149:1513–21.
 https://doi.org/10.1016/j.jaci.2022.022.
- 508 [18] Bourdillon AT, Edwards HA. Review of probiotic use in otolaryngology. Am J Otolaryngol 2021;42:102883. https://doi.org/10.1016/j.amjoto.2020.102883.
- [19] Cervin AU. The Potential for Topical Probiotic Treatment of Chronic Rhinosinusitis, a Personal
 Perspective. Front Cell Infect Microbiol 2017;7:530. https://doi.org/10.3389/fcimb.2017.00530.

- [20] Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal
 pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev
 2010:CD001176. https://doi.org/10.1002/14651858.CD001176.pub2.
- [21] Yazdi MH, Soltan Dallal MM, Hassan ZM, Holakuyee M, Agha Amiri S, Abolhassani M, et al.
 Oral administration of Lactobacillus acidophilus induces IL-12 production in spleen cell culture of
 BALB/c mice bearing transplanted breast tumour. Br J Nutr 2010;104:227–32.
 https://doi.org/10.1017/S0007114510000516.
- 519 [22] Shida K, Kiyoshima-Shibata J, Kaji R, Nagaoka M, Nanno M. Peptidoglycan from lactobacilli
 520 inhibits interleukin-12 production by macrophages induced by Lactobacillus casei through Toll-like
 521 receptor 2-dependent and independent mechanisms. Immunology 2009;128:e858-869.
 522 https://doi.org/10.1111/j.1365-2567.2009.03095.x.
- [23] Shida K, Kiyoshima-Shibata J, Nagaoka M, Watanabe K, Nanno M. Induction of interleukin-12 by
 Lactobacillus strains having a rigid cell wall resistant to intracellular digestion. J Dairy Sci
 2006;89:3306–17. https://doi.org/10.3168/jds.S0022-0302(06)72367-0.
- [24] Desrosiers M. Refractory chronic rhinosinusitis: pathophysiology and management of chronic
 rhinosinusitis persisting after endoscopic sinus surgery. Curr Allergy Asthma Rep 2004;4:200–7.
 https://doi.org/10.1007/s11882-004-0027-z.
- [25] Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al.
 Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015;152:S1–39. https://doi.org/10.1177/0194599815572097.
- 532 [26] PSTAT Validation Amerimmune n.d. https://www.amerimmune.com/pstat-validation (accessed
 533 October 17, 2023).
- [27] Ryherd M, Plassmeyer M, Alexander C, Eugenio I, Kleschenko Y, Badger A, et al. Improved panels
 for clinical immune phenotyping: Utilization of the violet laser. Cytometry B Clin Cytom
 2018;94:671–9. https://doi.org/10.1002/cyto.b.21532.
- [28] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021;596:583–9. https://doi.org/10.1038/s41586-021-03819-2.
- [29] Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF CHIMERAX :
 Structure visualization for researchers, educators, and developers. Protein Science 2021;30:70–82.
 https://doi.org/10.1002/pro.3943.
- [30] Dogan M, Kozhaya L, Placek L, Karabacak F, Yigit M, Unutmaz D. Targeting SARS COV 2
 infection through CAR T like bispecific T cell engagers incorporating ACE2. Clin & amp; Trans
 Imm 2022;11:e1421. https://doi.org/10.1002/cti2.1421.
- [31] Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, et al. Engineering Human MAIT Cells
 with Chimeric Antigen Receptors for Cancer Immunotherapy. The Journal of Immunology
 2022;209:1523–31. https://doi.org/10.4049/jimmunol.2100856.
- 549 [32] VCV000328593.9 ClinVar NCBI n.d.
 550 https://www.ncbi.nlm.nih.gov/clinvar/variation/328593/?new_evidence=true (accessed October 1, 2023).
- [33] Cho D-Y, Hunter RC, Ramakrishnan VR. The Microbiome and Chronic Rhinosinusitis. Immunol
 Allergy Clin North Am 2020;40:251–63. https://doi.org/10.1016/j.iac.2019.12.009.
- [34] Säemann MD, Parolini O, Böhmig GA, Kelemen P, Krieger P-M, Neumüller J, et al. Bacterial
 metabolite interference with maturation of human monocyte-derived dendritic cells. J Leukoc Biol
 2002;71:238–46.
- [35] Sogkas G, Atschekzei F, Schacht V, Von Falck C, Jablonka A, Jacobs R, et al. First Association of
 Interleukin 12 Receptor Beta 1 Deficiency with Sjögren's Syndrome. Front Immunol 2017;8:885.
 https://doi.org/10.3389/fimmu.2017.00885.
- [36] Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of Intracellular Phosphorylated STAT-4
 by Flow Cytometry. Clinical Immunology 2001;100:270–6. https://doi.org/10.1006/clim.2001.5078.

- Fieschi C. A novel form of complete IL-12/IL-23 receptor 1 deficiency with cell surface-expressed
 nonfunctional receptors. Blood 2004;104:2095–101. https://doi.org/10.1182/blood-2004-02-0584.
- [38] Hamilos DL. Host-microbial interactions in patients with chronic rhinosinusitis. Journal of Allergy
 and Clinical Immunology 2013;131:1263-1264.e6. https://doi.org/10.1016/j.jaci.2013.02.020.
- [39] Chung K-S, Choi JW, Shin J-S, Kim S-Y, Han H-S, Kim S-Y, et al. Strain-Specific Identification
 and In Vivo Immunomodulatory Activity of Heat-Killed Latilactobacillus sakei K040706. Foods
- 568 2021;10:3034. https://doi.org/10.3390/foods10123034.
- [40] Chiarella SE, Grammer LC. Immune deficiency in chronic rhinosinusitis: screening and treatment.
 Expert Rev Clin Immunol 2017;13:117–23. https://doi.org/10.1080/1744666X.2016.1216790.
- [41] Alpan O, Loizou D, Santos I, Ness B, Plandowski J. Impact of immune work-up on outcomes and the cost of care in patients with Chronic Rhinosinusitis. Allergy 2019;74:1802–5. https://doi.org/10.1111/all.13793.
- [42] Quinteiro-Filho WM, Brisbin JT, Hodgins DC, Sharif S. Lactobacillus and Lactobacillus cell-free
 culture supernatants modulate chicken macrophage activities. Res Vet Sci 2015;103:170–5.
 https://doi.org/10.1016/j.rvsc.2015.10.005.
- [43] Rocha-Ramírez LM, Pérez-Solano RA, Castañón-Alonso SL, Moreno Guerrero SS, Ramírez
 Pacheco A, García Garibay M, et al. Probiotic Lactobacillus Strains Stimulate the Inflammatory
 Response and Activate Human Macrophages. J Immunol Res 2017;2017:4607491.
 https://doi.org/10.1155/2017/4607491.
- [44] Ellis S, Lin EJ, Tartar D. Immunology of Wound Healing. Curr Derm Rep 2018;7:350–8.
 https://doi.org/10.1007/s13671-018-0234-9.
- [45] Eming SA, Krieg T, Davidson JM. Inflammation in Wound Repair: Molecular and Cellular
 Mechanisms. Journal of Investigative Dermatology 2007;127:514–25.
 https://doi.org/10.1038/sj.jid.5700701.
- [46] Raziyeva K, Kim Y, Zharkinbekov Z, Kassymbek K, Jimi S, Saparov A. Immunology of Acute and Chronic Wound Healing. Biomolecules 2021;11:700. https://doi.org/10.3390/biom11050700.
- [47] Dumitru C, Kabat AM, Maloy KJ. Metabolic Adaptations of CD4+ T Cells in Inflammatory
 Disease. Front Immunol 2018;9:540. https://doi.org/10.3389/fimmu.2018.00540.
- [48] Linehan JL, Harrison OJ, Han S-J, Byrd AL, Vujkovic-Cvijin I, Villarino AV, et al. Non-classical Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair. Cell 2018;172:784-796.e18. https://doi.org/10.1016/j.cell.2017.12.033.
- [49] Vemuri R, Gundamaraju R, Shinde T, Perera AP, Basheer W, Southam B, et al. Lactobacillus
 acidophilus DDS-1 Modulates Intestinal-Specific Microbiota, Short-Chain Fatty Acid and
 Immunological Profiles in Aging Mice. Nutrients 2019;11:1297.
- 596 https://doi.org/10.3390/nu11061297.
- 597
- 598

599 **Figure legends**:

- 600 Figure 1
- 601 Characterizing of the patient. A) Endoscopic photograph of the patient's sinus. B) Sanger
- sequencing of the *IL12Rb1* gene. C) Pedigree of the patient and her family. D) CD212
- 603 (IL12R β 1) expression on CD4 and CD20 lymphocytes.

- 605 **Figure 2**
- 606 Stimulation of PBMC with PMA and ionomycin. The percentages of CD3⁺/CD4⁺ lymphocytes
- that produces IL-17 (normal range 0.2%-2.2%) and IFNγ (normal range 3-30%) were determined
- 608 by flow cytometry.

609

- 610 **Figure 3**
- 611 The mutation affects IL-12 signaling. PBMC stimulated with IL-12, IL-18, IL-2 and
- 612 CD3&CD28 beads. The IFN γ production were measured in CD3⁺/CD4⁺ lymphocytes. The
- experiment was repeated three times. Representative plots are shown.

614

- 615 **Figure 4**
- 616 STAT4 phosphorylation in response to IL-12 stimulation. A) representative plots. B) Results
- from the patient, healthy controls and CVID patients. C) Four of the patient's children. "+"
- 618 indicates wt allele and "-" indicates the mutation.

619

- 620 **Figure 5**
- Effect of IL12R β 1 expression on IL-12 induced STAT4 phosphorylation in Jurkat cells.
- Histograms overlay representing pStat4 after stimulation of wild type or engineered Jurkat cells
- with wt IL12Rb2, wt IL12Rb1 or both receptors.

624

625 **Figure 6**

626	IL12Rb1 and IL12Rb2 engineered Jurkat cells. A) Expression analyzed by flow cytometry of
627	IL12Rb2 and IL12Rb1. B) Comparison of percent phosphorylated STAT4 expression in
628	engineered Jurkat cells expressing wild-type or mutant IL12Rb1 with or without IL12Rb2.
629	
630	Figure 7
631	STAT4 phosphorylation in Jurkat clones expressing different levels of IL-12Rb1. A) STAT4
632	phosphorylation after IL-12 stimulation. B) IL12Rb1 expression levels.
633	
634	Figure 8
635	Percent pSTAT4 positive cells after IL-12 stimulation of whole blood from CRS patients and
636	healthy controls.
637	
638	Figure 9
639	In vitro effects of lactobacilli on STAT4 phosphorylation. A) The percentage of
640	pSTAT4/CD45RO cells for the different conditions indicated in the figure. B) Effect of IL-12
641	neutralizing antibodies on lactobacilli induced STAT4 phosphorylated.
642	
643	Figure 10
644	Lactobacilli in post-surgery setting. Patient data on the total number of outpatient visits for one
645	year following surgery and pSTAT4 levels before and approximately six months after L. sakei
646	treatments.



А





В











































В Reduction in lactobacilli induced STAT4 phosphorylation by αlL-12



